A Study of Pyridostigmine in Postural Tachycardia Syndrome


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 06-002442
    NCT ID: NCT00409435
    Sponsor Protocol Number: 06-002442

About this study

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Diagnosis of postural tachycardia syndrome using the following criteria:
    • Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
    • Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
  • Both criteria must be fulfilled.

Exclusion Criteria:

  • Pregnant or lactating women
  • Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
  • Hypothyroidism or hyperthyroidism
  • Clinically significant coronary artery disease
  • Medications that could interfere with autonomic testing
  • Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Phillip Low, M.D.

Open for enrollment

Contact information:

Tonette Gehrking CAP




Mayo Clinic Footer